Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)
- PMID: 39325987
- PMCID: PMC11590041
- DOI: 10.1002/hon.3312
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)
Abstract
Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (n = 24). The most common histological subtype was diffuse large B-cell lymphoma (DLBCL, n = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first-line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow-up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5-year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause-specific, and progression-free survival in patients with DLBCL.
Keywords: CNS prophylaxis; chemotherapy; female reproductive system; lymphoma.
© 2024 The Author(s). Hematological Oncology published by John Wiley & Sons Ltd.
Conflict of interest statement
MCP: travel grant Beigene, Janssen; EZ: Research Funding (Institutional): AstraZeneca, Beigene, Celgene/BMS, Incyte, Janssen, Roche; Honoraria (Medical educational event): Abbvie; Honoraria (Advisory Board): AbbVie, BeiGene, BMS, Curis, Eli/Lilly, Incyte, Ipsen, Merck, Miltenyi Biomedicine, Roche; Travel grants: AstraZeneca, BeiGene, Janssen, and Gilead; AS: Institutional funding for clinical trials: Abbvie; ADC Therapeutics; Amgen, Astra Zeneca; Bayer; BMS; Cellestia; Incyte, Loxo Oncology; Merck MSD; Novartis; Pfizer; Philogen; Prelude Therapeutics; Roche; Consultant/expert testimony/advisory board (institutional): Debiopharm, Janssen, AstraZeneca, Incyte, Eli Lilly, Novartis, Roche, Loxo Oncology; Travel grant: Incyte; Astra Zeneca; all the other coauthors have not COI.
References
-
- Woodruff JD, Noli C, Novak ER. Lymphoma of the ovary. A study of 35 cases from the ovarian tumor registry of the American gynecological society. Am J Obstet Gynecol. 1963;85:912‐918. - PubMed
-
- Kaplan EJ. Commenting on “HIV‐associated primary cervical non‐Hodgkin's lymphoma and two other cases of primary pelvic non‐Hodgkin's lymphoma” by Pham et al. 90:204‐6. Gynecol Oncol. 2004;93(3):719‐720. author reply 20. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources